Early response monitoring during [¹⁷⁷Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study.

"Declarations Ethics approvalThis study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University Basel, Basel, Switzerland (EKNZ: 2021–01271). Consent to participateInformed consent was obtained from all individual participants included in the study. Competing interestsDamian Wild received grants from Siemens Healthineers. All other authors have no relevant financial or non-financial interests to disclose. Competing interests Damian Wild received grants from Siemens Healthineers. All other authors have no relevant financial or non-financial interests to disclose."

"Funding Open access funding provided by University of Basel This study uses data from a national Swiss-wide cancer registry, which was partly funded by the swissHADRON foundation (Stiftung swissHADRON)."

"This was a single-center, retrospective study done at the University Hospital Basel as part of a national Swiss-wide cancer registry study analyzing data from 07/2020 to 04/2022. Data collection was part of a national registry study approved by the Swiss Federal Office of Public Health (EKNZ: 2021–01271)."